High Dose Nimodipine Treatment Adjunct - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000332

Purpose

The purpose of this study is to determine if nimodipine is more effective than placebo in reducing stimulated craving for cocaine in cocaine dependent individuals denied access to cocaine in inpatient unit.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Nimodipine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	High Dose Nimodipine Pharmacotherapy Adjunct

Resource links provided by NLM:

Drug Information available for: Nimodipine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Stimulated and non-stimulated craving
Stimulated and non-stimulated withdrawal
Anxiety, depression
Heart rate

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	22 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000332

Locations

United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

Steven Deutsch, M.D.

Washington DC VA

More Information

No publications provided

Study ID Numbers:	NIDA-3-0009-1, Y01-3-0009-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000332 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Disorders of Environmental Origin
Calcium Channel Blockers
Cardiovascular Agents
Antihypertensive Agents

Pharmacologic Actions
Membrane Transport Modulators
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Nimodipine

ClinicalTrials.gov processed this record on November 09, 2009